Alpha Teknova, Inc. 10-Q

Item 2 . Management’s Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed financial statements and related notes thereto included in Part I, Item I of this Quarterly Report on Form 10-Q and with our audited financial statements and related notes thereto for the year ended December 31, 2025, included in the 2025 Annual Report on Form 10-K (the 2025 Annual Report on Form 10-K) filed on March 2, 2026, with the Securities and Exchange Commission (SEC). For a discussion of factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis and elsewhere in this Quarterly Report on Form 10-Q, you should review the risk factors identified in Part I, Item 1A, Risk Factors, of our 2025 Annual Report on Form 10-K and in Item 1A, Risk Factors, of this Quarterly Report on Form 10-Q. As in Item 1. of this Quarterly Report on Form 10-Q, in this Item 2, unless the context otherwise requires, the terms “Teknova,” the “Company,” “we,” “us,” and “our” refer to Alpha Teknova, Inc. Overview Since our founding in 1996, we have been producing critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Our approximately 3,000 customers span the entire continuum of the life sciences market, including leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Our Company is built around our knowledge, methods, and know-how in our proprietary manufacturing processes, which are highly adaptable and configurable. These proprietary processes enable us to manufacture and deliver high-quality, custom, made-to-order products with short turnaround times and at scale, across all stages of our customers’ product development, from early research through commercialization. We have two primary product categories: (i) Lab Essentials, and (ii) Clinical Solutions. Our products cross all stages of development, from early research through commercialization. We offer three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification. Our liquid microbial culture media and supplements and molecular biology reagents are available in both of our two primary product categories; pre-poured media plates are available in our Lab Essentials category only. We are ISO 13485:2016 certified, enabling us to manufacture products for use in diagnostic and therapeutic applications. Our certification allows us to offer solutions across the entire customer product development workflow, supporting our customers’ need for materials in greater volume and that meet increasingly stringent quality requirements as they scale from research to commercialization. We manufacture our products at our Hollister, California headquarters and stock inventory of raw materials, components, and finished goods at that campus. We rely on a limited number of suppliers for certain raw materials, and we have no long-term supply arrangements with our suppliers, as we order on a purchase order basis. We ship our products directly from our warehouse in Hollister, California, to our customers and distributors, generally pursuant to purchase orders. We typically recognize revenue when products are shipped. We generated revenue of $11.1 million during the three months ended March 31, 2026, which represented an increase of $1.3 million compared to revenue of $9.8 million during the three months ended March 31, 2025. For the three months ended March 31, 2026 and 2025, only 4.7% and 5.3%, respectively, of our revenue was generated from customers located outside of the United States. Our sales outside of the United States are denominated in U.S. Dollars. We primarily generate sales through direct channels and a small salesforce, supported by an established network of distributors. We had an operating loss of $4.3 million during the three months ended March 31, 2026, compared to an operating loss of $5.0 million during the three months ended March 31, 2025. While our expenses may fluctuate over the short term, we expect our expenses will increase in future periods, but at a slower rate, in connection with our ongoing activities as we: 17 • attract, hire, and retain qualified personnel; • invest in processes and infrastructure to improve operating efficiency and expand capacity at our facilities, including the ramp up of our new warehouse and distribution facility; • build our brand awareness and market presence through targeted marketing initiatives, strategic partnerships, and expanded sales efforts; and • increase investment in selling and marketing activities to drive customer acquisition, strengthen channel relationships, and support revenue growth across existing and new markets. Impact of Broader Economic Trends on Our Business We continue to closely monitor economic uncertainty in the U.S. and abroad. General inflation in the U.S. rose in recent years to levels not experienced in recent decades. While the rate of inflation has moderated in recent years, general inflation, including rising prices for our raw materials and other inputs, tariffs, as well as rising salaries and other expenses, can negatively impact our business by increasing our cost of sales and operating expenses. Inflation, together with uncertainty regarding future interest rate changes, and broader macroeconomic uncertainty, may cause our customers to reduce, delay, or cancel orders for our goods and services, thereby causing a decrease in or change in the timing of sales of our products and services. We cannot predict the impact of future inflation and interest rate changes on the results of our operations. Furthermore, changes to tariff and related international trade policy that began in 2025 has created uncertainty about the broader economy and our business. For further information regarding the impact of these economic factors on the Company, please see the risk factors identified in Part I, Item 1A, Risk Factors, of our 2025 Annual Report on Form 10-K. Results of Operations Comparison of the Three Months Ended March 31, 2026, and Three Months Ended March 31, 2025 The following tables set forth our results of operations for the three months ended March 31, 2026 and 2025 (dollars in thousands): For the Three Months Ended March 31, 2026 2025 $ Change % Change Revenue $ 11,077 $ 9,795 $ 1,282 13.1 % Cost of sales 7,293 6,788 505 7.4 % Gross profit 3,784 3,007 777 25.8 % Operating expenses: Research and development 609 552 57 10.3 % Sales and marketing 2,128 1,640 488 29.8 % General and administrative 5,058 5,492 (434 ) (7.9 )% Amortization of intangible assets 287 287 — — Total operating expenses 8,082 7,971 111 1.4 % Loss from operations (4,298 ) (4,964 ) 666 (13.4 )% Other (expenses) income, net Interest expense, net (219 ) (144 ) (75 ) 52.1 % Other adjustment to loan exit fee — 485 (485 ) (100.0 )% Other income 9 — 9 100.0 % Total other (expenses) income, net (210 ) 341 (551 ) (161.6 )% Loss before income taxes (4,508 ) (4,623 ) 115 (2.5 )% Provision for income taxes 47 22 25 113.6 % Net loss $ (4,555 ) $ (4,645 ) $ 90 (1.9 )% 18 Revenue Our revenue disaggregated by product category for the three months ended March 31, 2026 and 2025, was as follows (dollars in thousands): For the Three Months Ended March 31, 2026 2025 $ Change % Change Lab Essentials $ 8,395 $ 8,117 $ 278 3.4 % Clinical Solutions 2,145 1,162 983 84.6 % Other 537 516 21 4.1 % Total revenue $ 11,077 $ 9,795 $ 1,282 13.1 % Total revenue was $11.1 million and $9.8 million for the three months ended March 31, 2026 and 2025, respectively. Lab Essentials revenue was $8.4 million for the three months ended March 31, 2026, an increase of $0.3 million, or 3.4%, compared to $8.1 million for the three months ended March 31, 2025. The increase in Lab Essentials revenue was attributable to higher average revenue per customer, partially offset by a decreased number of customers. Clinical Solutions revenue was $2.1 million for the three months ended March 31, 2026, an increase of $1 .0 million, or 84 .6 %, compared to $1.2 million for the three months ended March 31, 2025. The increase in Clinical Solutions revenue was attributable to an increased number of customers and, to a slightly lesser extent higher average revenue per customer. Our revenue disaggregated by geographic region, for the three months ended March 31, 2026 and 2025, was as follows (dollars in thousands): For the Three Months Ended March 31, 2026 2025 $ Change % Change United States $ 10,561 $ 9,272 $ 1,289 13.9 % International 516 523 (7 ) (1.3 )% Total revenue $ 11,077 $ 9,795 $ 1,282 13.1 % Revenue from U.S. sales was $10.6 million and $9.3 million for the three months ended March 31, 2026 and 2025, respectively. Revenue from U.S. sales as a percentage of our total revenue was consistent period over period, representing 95.3% and 94.7% of our total revenue during the three months ended March 31, 2026 and 2025, respectively. Revenue from international sales was $0.5 million for each of the three months ended March 31, 2026 and 2025, respectively. Revenue from international sales as a percentage of our total revenue was also consistent period over period, representing 4.7% and 5.3% of our total revenue during the three months ended March 31, 2026 and 2025, respectively. Gross profit Our gross profit for the three months ended March 31, 2026 and 2025, was as follows (dollars in thousands): For the Three Months Ended March 31, 2026 2025 $ Change % Change Cost of sales $ 7,293 $ 6,788 $ 505 7.4 % Gross profit 3,784 3,007 777 25.8 % Gross profit % 34.2 % 30.7 % Gross profit percentage was 34.2% and 30.7% for the three months ended March 31, 2026 and 2025, respectively. The increase in gross profit was primarily driven by higher revenue. Operating expenses Our operating expenses for the three months ended March 31, 2026 and 2025, were as follows (dollars in thousands): 19 For the Three Months Ended March 31, 2026 2025 $ Change % Change Research and development $ 609 $ 552 $ 57 10.3 % Sales and marketing 2,128 1,640 488 29.8 % General and administrative 5,058 5,492 (434 ) (7.9 )% Amortization of intangible assets 287 287 — — Total operating expenses $ 8,082 $ 7,971 $ 111 1.4 % Research and development expenses were consistent at $0.6 million and $0.6 million for the three months ended March 31, 2026 and 2025, respectively. Sales and marketing expenses were $2.1 million and $1.6 million for the three months ended March 31, 2026 and 2025, respectively. The increase was primarily driven by higher headcount and increased marketing expenses. General and administrative expenses were $5.1 million and $5.5 million for the three months ended March 31, 2026 and 2025, respectively. The decrease was primarily driven by lower stock-based compensation expense and professional fees. Amortization of intangible assets was consistent at $0.3 million for each of the three months ended March 31, 2026 and 2025. Other (expenses) income, net Our other (expenses) income, net for the three months ended March 31, 2026 and 2025, were as follows (dollars in thousands): For the Three Months Ended March 31, 2026 2025 $ Change % Change Interest expense, net $ (219 ) $ (144 ) $ (75 ) 52.1 % Other adjustment to loan exit fee — 485 (485 ) (100.0 )% Other income 9 — 9 100.0 % Total other (expenses) income, net $ (210 ) $ 341 $ (551 ) (161.6 )% Total other (expenses) income, net was an expense of $0.2 million for the three months ended March 31, 2026, compared to income of $0.3 million for the three months ended March 31, 2025. The increase in total other expense, net was primarily attributable to the $0.5 million adjustment recognized on the exit fee concurrent with the refinancing of our credit agreement during the three months ended March 31, 2025. Provision for income taxes Our provision for income taxes for the three months ended March 31, 2026 and 2025, was as follows (dollars in thousands): For the Three Months Ended March 31, 2026 2025 $ Change % Change Provision for income taxes $ 47 $ 22 $ 25 113.6 % Effective tax rate (1.0 )% (0.5 )% Our income taxes were not significant for either the three months ended March 31, 2026 or 2025. The effective tax rates for the three months ended March 31, 2026 and 2025 were (1.0%) and (0.5)%, respectively. The effective tax rates differ from the federal statutory rate primarily due to operating losses not expected to produce an income tax benefit. Liquidity and Capital Resources The primary sources of financing for our operations are our (i) registered direct offering and concurrent private placement completed in September 2023, which resulted in aggregate gross proceeds of $22.9 million before deducting offering expenses of $0.4 million and the prepayment of $10.0 million of the Term Loan, and (ii) private placement completed in July 2024, which resulted in aggregate gross proceeds of $15.4 million before deducting offering expenses of $0.2 million. Our principal liquidity requirements are to fund our operations and capital expenditures. During the three months ended March 31, 2026, we incurred net losses of $4.6 million. In addition, as of March 31, 2026, we had an accumulated deficit of $140.3 million and $13.2 million in borrowings outstanding under our Term Loan (defined below). As of March 31, 2026, we had $24.8 million in net working capital, which included $17.8 million in cash and cash equivalents and short-term investments. Our material 20 cash requirements from known contractual obligations and commitments relate primarily to operating leases for our office, manufacturing, warehouse, and distribution facilities at March 31, 2026. See “Notes to Financial Statements—Note 9. Leases,” for a discussion of our lease obligations reflected on our Condensed Balance Sheets. In addition to our existing cash and cash equivalents and short-term investments, our principal source of liquidity is our credit facility. On March 3, 2025, we entered into the Second Amended and Restated Credit Agreement with MidCap Financial (Midcap) Trust which provides for loan commitments in an aggregate amount of up to $28.245 million consisting of a $23.245 million senior secured term loan (Term Loan) and a $5.0 million working capital facility (Revolver). The Term Loan consists of the $12.135 million balance outstanding under the previous term loan, plus an additional $1.110 million related to the exit fee that would otherwise have been due upon closing of the Second Amended and Restated Term Loan Credit Agreement, as well as an additional tranche of $10.0 million that may become available for use in an acquisition, with MidCap’s consent. As of March 31, 2026, there were no amounts outstanding under the Revolver, and $3.6 million was available based on borrowing base estimates. The Second Amended and Restated Credit Agreement includes minimum net revenue requirements that are measured on a trailing twelve-month basis and a minimum cash requirement throughout the term of the agreement. The minimum cash requirement is $8.0 million, which includes cash and cash equivalents as well as short-term investments in U.S. Treasuries. We were in compliance with our financial covenants under the terms of the Second Amended and Restated Credit Agreement as of March 31, 2026. See “Notes to Financial Statements—Note 12. Long-Term Debt, Net” for a more detailed discussion of the material terms of our Second Amended and Restated Credit Agreement. On July 10, 2025, we filed a “shelf” registration statement on Form S-3 (Reg. No. 333-288613) with the SEC, which was declared effective on July 16, 2025. This shelf registration statement, which includes a base prospectus, allows us at any time to offer any combination of securities described in the prospectus in one or more offerings for our own account in an aggregate amount up to $225 million. The Form S-3 is intended to provide us flexibility to conduct registered sales of our securities, subject to market conditions and our future capital needs. The terms of any future offering under the shelf registration statement will be established at the time of such offering and will be described in a prospectus supplement filed with the SEC prior to the completion of any such offering. The following table sets forth, for the periods indicated, net cash flows used in operating activities, provided by investing activities, and used in financing activities (in thousands): For the Three Months Ended March 31, 2026 2025 Net cash used in operating activities $ (3,359 ) $ (4,103 ) Net cash provided by investing activities 1,841 3,824 Net cash used in financing activities (88 ) (52 ) Net decrease in cash and cash equivalents $ (1,606 ) $ (331 ) Operating Activities Net cash used in operating activities for both the three months ended March 31, 2026 and 2025 consisted primarily of net loss, adjusted for certain non-cash items, and changes in working capital and other operating activities. Net cash used in operating activities was $3.4 million for the three months ended March 31, 2026, which primarily consisted of net loss of $4.6 million plus net adjustments for non-cash charges of $2.7 million, offset by net changes in operating assets and liabilities of $1.5 million. The primary non-cash adjustments to net loss included $1.6 million of depreciation and amortization, $0.7 million of stock-based compensation, and a $0.4 million provision for inventory. The main drivers of the changes in operating assets and liabilities were a $1.1 million increase in accounts receivable, a $0.8 million decrease in accrued liabilities, and a $0.2 million increase in inventories, partially offset by a $0.3 million increase in accounts payable, and a $0.2 million decrease in prepaid expenses and other current assets. Net cash used in operating activities was $4.1 million for the three months ended March 31, 2025, which primarily consisted of net loss of $4.6 million plus net adjustments for non-cash charges of $2.3 million, offset by net changes in operating assets and liabilities of $1.8 million. The primary non-cash adjustments to net loss included $1.6 million of depreciation and amortization, $0.9 million of stock-based compensation, and $0.4 million provision for inventory, partially offset an adjustment to the loan exit fee of $0.5 million, and amortization of the discount on short-term investments of $0.2 million. The main drivers of the changes in operating assets and liabilities were a $1.3 million increase in accounts receivable, a $1.0 million decrease in accrued liabilities, and a $0.2 million increase in inventories, partially offset by a $0.7 million increase in accounts payable. 21 Investing Activities Net cash provided by investing activities was $1.8 million for the three months ended March 31, 2026, which consisted of maturities of short-term investments of $6.0 million, partially offset by purchases of short-term investments of $3.9 million and purchases of property, plant, and equipment of $0.2 million. Net cash used in investing activities was $3.8 million for the three months ended March 31, 2025, which consisted of maturities of short-term investments of $6.0 million, partially offset by purchases of short-term investments of $2.0 million and purchases of property, plant, and equipment of $0.2 million. Financing Activities Net cash provided by financing activities was $0.1 million for the three months ended March 31, 2026, which was primarily attributable to repayment of financed insurance premiums of $0.1 million. Net cash used in financing activities was $0.1 million for the three months ended March 31, 2025, which was primarily attributable to payment of exit fee costs of $1.1 million and repayment of financed insurance premiums of $0.1 million, largely offset by proceeds from long-term debt of $1.1 million. Critical Accounting Policies and Estimates For a discussion of our critical accounting estimates, refer to "Management ’ s Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 and the notes to our financial statements in Part II, Item 8 of our 2025 Annual Report on Form 10-K. See also “Notes to Financial Statements—Note 2. Basis of Presentation and Summary of Significant Accounting Policies,” to our condensed financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. There have been no material changes to our critical accounting estimates since our 2025 Annual Report on Form 10-K. Emerging Growth Company and Smaller Reporting Company We qualify as an “emerging growth company” as defined in the JOBS Act. As long as we qualify as an emerging growth company, we may take advantage of certain exemptions from various reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include, but are not limited to: • reduced obligations with respect to financial data, including presenting only two years of audited financial statements; • an exemption from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act; • reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements, and registration statements; and • exemptions from the requirements of holding non-binding advisory votes on executive compensation or golden parachute arrangements. In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from adopting new or revised accounting standards, and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies or that have opted out of using such extended transition period, which may make comparison of our financial statements with those of other public companies more difficult. We may take advantage of these reporting exemptions until we no longer qualify as an emerging growth company, or, with respect to adoption of certain new or revised accounting standards, until we irrevocably elect to opt out of using the extended transition period. Under the JOBS Act, we will remain an emerging growth company until the earliest to occur of: • the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; • the last day of our fiscal year following the fifth anniversary of the date of the closing of our initial public offering, which we completed in June 2021; • the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; and • the date on which we are deemed to be a “large accelerated filer” under the Securities Exchange Act of 1934, as amended (the Exchange Act) (i.e., the first day of the fiscal year after we have (i) more than $700.0 million in outstanding common equity held by our non-affiliates, measured each year on the last business day of our most recently completed second fiscal quarter, and (ii) been public for at least 12 months). 22 We are also a “smaller reporting company” as defined in Rule 12b-2 under the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that (i) the market value of our voting and non-voting common stock held by non-affiliates equals or exceeds $250.0 million measured on the last business day of our most recently completed second fiscal quarter, and our annual revenues are more than $100.0 million during the most recently completed fiscal year or (ii) the market value of our voting and non-voting common stock held by non-affiliates equals or exceeds $700.0 million measured on the last business day of our most recently completed second fiscal quarter. Recent Accounting Pronouncements A description of recent accounting pronouncements that may potentially impact our financial position, results of operations, or cash flows is disclosed in “Notes to Financial Statement—Note 2. Basis of Presentation and Summary of Significant Accounting Policies,” to our condensed financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. Item 3 . Quantitative and Qualitative Disclosures About Market Risk. We are a smaller reporting company, as defined in Rule 12b-2 under the Exchange Act for this reporting period and are not required to provide the information required under this item.